Hiding EGFR-Targeting Antibody Improves Its Safety Profile
By Anette Breindl
Wednesday, October 16, 2013
A team from South San Francisco based Cytomx Therapeutics Inc. reported today that it has developed an EGFR-targeting “probody” that was activated specifically in the tumor microenvironment, allowing its delivery at higher doses than conventional antibodies to both mice and primates. The experiments, Cytomx’ chief scientific officer Henry Lowman told BioWorld Today, showed that “antibodies can be masked and locally activated,” and that in doing so, “safety is really improved.” They were published in the Oct. 17, 2013, issue of Science Translational Medicine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.